The therapeutic intent of Quadriderm is to provide comprehensive support for skin conditions requiring a multi-action approach. The product’s combination of four active agents is formulated as an Anti-Inflammatory, Antipruritic, Antibacterial, and Antifungal agent, and is applied across domains where additional symptomatic support is needed in complicated dermatoses.

---

Key Therapeutic Focus

This cream is commonly used to help address inflammatory skin disorders, such as certain types of eczema and dermatitis, when the condition is complicated by co-existing microbial pathogens. It is also relevant for managing specific Tinea infections (like athlete's foot or ringworm) that involve significant inflammation. The formula is applied in clinical settings that involve acute or unstable symptom patterns, helping to ease pronounced symptoms of inflammation, including intense pruritus (itching), redness, and swelling. By acting against these factors simultaneously, it contributes to improved day-to-day comfort and supports maintaining a sense of stability when complex skin symptoms become more noticeable and disruptive.

---

Quick Fact Block

Quick Fact: Relief for Inflammation and Mixed Infections
Primary Indication: Inflammatory skin disorders complicated by susceptible bacterial or fungal pathogens.
Main Symptom Relief: Intense itching (pruritus), redness (erythema), and swelling.
Key Benefit: Provides support that helps ease the overall symptom burden and assists with maintaining functional stability.

Regulatory References

1. Philippine Food and Drug Administration

Who Can and Cannot Use Quadriderm?

Regulatory documents define strict population eligibility for Quadriderm, focusing on contraindications and restricted use due to the product's potent combination of ingredients.

---

Contraindicated and Restricted Populations

Category	Regulatory Status	Key Exclusion Criteria
Absolute Contraindications	Must Not Use	Known hypersensitivity to any active ingredient (e.g., Betamethasone, Neomycin/Gentamicin, Clotrimazole) or excipients; presence of viral skin infections like herpes simplex or varicella; skin tuberculosis.
Pediatric Use	Not Recommended/Not Established	Children under 12 years due to unestablished safety and increased risk of systemic absorption. Use for diaper rash is also not recommended.
Physiological/Comorbid	Use with Caution/Restricted	Pregnant or breastfeeding women (use is generally restricted to risk vs. benefit assessment; avoid application to the breast area); patients with impaired renal (kidney) function; extensive or prolonged use in individuals with conditions like diabetes or glaucoma.

---

Official eligibility ensures that the medicine is applied only within labeled safety parameters, primarily restricting use in vulnerable populations and those with specific pre-existing skin conditions that could be worsened by the corticosteroid component.

Interactions with other medicines and products

The interaction profile for Quadriderm topical cream is derived from the potential for its potent active ingredients—Betamethasone Dipropionate and Gentamicin Sulfate—to be absorbed systemically, particularly when applied over large areas or damaged skin. Officially documented statements establish restrictions to mitigate risks associated with this potential absorption.

Interaction-Related Restrictions

Category	Regulatory Statement
Additive Toxicity Risk	Avoid concurrent and/or sequential use with other neurotoxic or nephrotoxic drugs (e.g., Vancomycin, Tobramycin) due to the risk of additive toxicity from the Gentamicin component.
Diuretic Interaction	Avoid concurrent use with potent diuretics (e.g., Furosemide, Ethacrynic acid) as these may enhance aminoglycoside toxicity, including the risk of ototoxicity.
Exposure Modification	Co-administration with strong metabolic inhibitors (e.g., Ritonavir) may inhibit corticosteroid metabolism, potentially leading to increased systemic exposure of the Betamethasone component.

Specific Interaction Notes

• Diagnostic Test Interference: The Clioquinol component can interfere with the results of thyroid function tests due to its iodine content.
• Population Note: Patients with liver failure are noted to be at an increased risk for systemic adverse effects related to the Betamethasone component due to reduced clearance.

Connection to the overall interaction profile

Regulatory documents define the product’s interaction structure around the pharmacodynamic risk of additive toxicity posed by the Gentamicin component and the pharmacokinetic risk of increased systemic exposure of the Betamethasone component when clearance is compromised or when metabolic inhibitors are co-administered. The profile does not document specific food, alcohol, or mandatory timing-based separation requirements.

How Quadriderm Works

Betamethasone dipropionate is a synthetic corticosteroid that exerts its effects via binding and activation of intracellular glucocorticoid receptors. This receptor-mediated mechanism modulates the transcription of various genes, inhibiting the expression of inflammatory proteins, including phospholipase A2. This action curtails the release of pro-inflammatory mediators such as kinins, histamine, and eicosanoids, leading to the physiological modulation of capillary permeability and a reduction in leukocyte migration.

Gentamicin is an aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit of susceptible bacteria. This interaction interferes with the initiation complex for peptide chain formation and causes misreading of the mRNA template, thereby inhibiting bacterial protein synthesis and disrupting cell metabolism and function.

Clotrimazole is an imidazole antifungal agent that inhibits C-14 demethylase, a key enzyme in the fungal biosynthesis pathway of ergosterol. The resulting depletion of ergosterol, a critical component of the fungal cell membrane, leads to altered membrane fluidity and permeability, causing intracellular leakage.

Instruction Map: How to use Quadriderm — Administration Overview

This map synthesizes the high-level administration and dosing instructions for the topical combination product Quadriderm.

---

Administration Scope

Instruction	Detail
Route of administration	Topical (Cutaneous application to the skin surface only). It is not for oral, ophthalmic, or intravaginal use.
Dosing schedule	Application involves gently massaging a thin film of the cream to cover the entire affected skin area. Excessive amounts should be avoided.
Frequency and timing	Typically applied once or twice daily (BID), often in the morning and at night. Treatment should be discontinued once clinical control of the condition is achieved.
Preparation requirements (if applicable)	The affected area should be cleansed and dried before each application. Hands must be washed after use.
Age-group administration rules	Use in children younger than 12 years of age is generally not recommended or should be strictly limited in duration due to the components' potency.
Missed-dose rules	If an application is missed and it is almost time for the next scheduled dose, the missed dose should be skipped to avoid double application.
Special procedural conditions	The cream should not be used with occlusive dressings (bandages or wraps) unless explicitly directed by a healthcare professional. Avoid applying the cream to the face, groin, or axillae without specific guidance.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Topical (Non-systemic delivery).
Frequency pattern	Multiple times per day (once or twice daily).
Product Standards	Governed by established pharmaceutical standards for clinical use.
Use-context constraints	Course Duration: Therapy is short-term and typically not to exceed four weeks for continuous use in specific conditions.

---

Resulting Procedural Structure

Standard step sequence:

• Cleanse and dry the specific affected skin area.
• Gently massage a thin film of the cream onto the area to cover it completely.
• Apply the dose once or twice daily according to the prescribed frequency.
• Discontinue use when clinical control of the condition is achieved.

Connection to the overall use protocol (2–4 sentences): The usage protocol standardizes Quadriderm's administration as a topical cream with a defined once or twice-daily frequency. This protocol is defined by short-term duration limits and constraints on application, such as avoiding occlusive dressings and sensitive areas, which collectively define the required procedural standard for the medicine.

Research evidence / Overview of Studies for Quadriderm

---

Evidence for Use in Inflammatory Dermatoses Complicated by Mixed Microbial Pathogens

Research explored the use of the four-component topical cream (corticosteroid, antibiotic, two antifungals) in the context of inflammatory dermatoses that are complicated by co-existing bacterial and fungal pathogens. Studies included Randomized Controlled Trials (RCTs) and Comparative Clinical Trials where this fixed-dose combination was evaluated in adults and adolescents diagnosed with conditions like infected eczema or cutaneous candidiasis. This research primarily monitored short-term symptom changes.

Studies monitored outcomes related to physical discomfort and inflammatory states by measuring changes in redness (erythema) and itching (pruritus) over defined time intervals. Researchers also examined the microbiological status of the skin site, monitoring the presence of susceptible bacterial and fungal pathogens following the study period. Findings describe patterns observed in these studies, with results often structured as comparative measurements against other multi-ingredient topical creams.

---

Long-Term Studies and Evidence Gaps

The clinical research conducted to date has largely focused on acute, short-term treatment periods, typically spanning up to four weeks (28 days). Because follow-up durations were limited, long-term effects are not fully established. There is limited information regarding the maintenance of symptom control or patterns of recurrence following the study period.

Data for certain groups remain insufficient; for instance, few data are available regarding assessment in younger children (under 12 years of age). The overall evidence quality was assessed as Moderate-Low. This is due to the limited body of dedicated, product-specific Randomized Controlled Trials (RCTs) for the exact four-component formulation in major scientific registries. Comparative evidence is also lacking for certain research scenarios, such as comparisons against single-active component therapies.

Common questions about Quadriderm (FAQ)

Q: What is the purpose of Quadriderm?

According to official product information, Quadriderm is indicated for the topical treatment of certain inflammatory skin disorders. These conditions are typically those that are complicated by secondary infections caused by susceptible bacterial or fungal pathogens. The cream combines a corticosteroid for inflammation with anti-infective agents to address the mixed nature of the skin problem.

---

Q: Do I need a prescription to get Quadriderm?

Regulatory classification generally places this medication as a prescription-only medicine (POM). This classification indicates that dispensing the product requires a valid prescription from an authorized healthcare professional. This is due to the potent nature of its active ingredients.

---

Q: How long am I supposed to use Quadriderm cream?

Official prescribing information states that treatment is intended to be discontinued once clinical control of the condition has been achieved. Generally, continuous use is intended to be for short-term periods only. According to information derived from clinical studies, continuous treatment typically does not exceed four weeks.

---

Q: What should I do if I swallow Quadriderm cream by accident?

This product is strictly for external, topical use on the skin surface. In the event of accidental ingestion, immediate professional medical attention should be sought. You should contact emergency medical services or a poison control center right away for specific guidance.

---

Q: How should I dispose of an expired tube of Quadriderm?

To help ensure safety and prevent environmental harm, proper disposal procedures are outlined in official guidelines. You should not flush the cream down the toilet or pour it into any drain. Instead, unused or expired medication should be discarded according to local regulations or via an established medicine take-back program.

---

Q: What happens if I stop using Quadriderm too soon?

Official product information for corticosteroid-containing products notes that prematurely stopping treatment may potentially lead to a recurrence or rebound worsening of the original skin condition. The medication is intended to be used until the condition is clinically controlled, as directed by a healthcare professional.

Storage and Disposal Requirements

Quadriderm cream must be stored strictly according to regulatory guidelines to maintain its stability. The product should be kept at controlled room temperature, typically between 20° to 25°C (68° to 77°F), or in a range not exceeding 30°C. It is mandatory to protect the cream from freezing and excessive heat or moisture.

Handling and Safety

The container must be kept tightly closed when not in use. Crucially, the medicine must be stored out of the sight and reach of children.

Disposal

Any unused or expired product must be disposed of properly. Do not flush the cream down the toilet or pour it into a drain. It must be discarded according to local regulations or through established medicine take-back programs.